Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Pembrolizumab
DRUG: Trebananib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]